AstraZeneca DIGITAL

Enterprise Technology Stack & Vendor Relationships

• A 2026 AstraZeneca security-platform leadership vacancy identifies Wiz as a core cloud-security platform and Claroty as a core network and operational-technology security platform; it assigns roadmap and lifecycle responsibility for both and identifies Wiz, Microsoft, Claroty and Proofpoint as strategic vendor partnerships.¹

• This supports an AstraZeneca enterprise-platform relationship and lifecycle-governance remit for Wiz and Claroty, but does not identify a specific product module, implementation site, deployment date, technical architecture, data category, telemetry destination, support-access location, contract value, or use within AstraZeneca Israel.¹

• AstraZeneca describes cybersecurity as a global capability protecting drug-discovery, clinical-development, manufacturing and medicine-delivery infrastructure, but does not attribute that capability to a particular Wiz or Claroty deployment.²

• AstraZeneca Israel identifies Microsoft and Cisco as PlayBeyondBio collaboration partners during 2019–20, while a 2022 BeyondBio SCALE announcement named Accenture, AWS and Clalit Health Services as programme partners; neither record establishes those companies as AstraZeneca’s general enterprise-technology suppliers or identifies products, deployments, data access or Israeli hosting.³

• No public evidence identified, in the reviewed corporate, vendor, procurement and targeted-search materials, of AstraZeneca licensing or integrating Check Point, SentinelOne, CyberArk, NICE, Verint, Palo Alto Networks, or a named systems integrator deploying an Israeli-origin product for AstraZeneca.^{1, 3, 4}

• No public evidence identified that the Wiz or Claroty relationships establish Israeli processing or support access to AstraZeneca sensitive data, a particular Israeli deployment, or an Israeli state, military, intelligence, police, border, settlement or occupation downstream use.¹

Surveillance, Biometrics & Retail Technology

• No public evidence identified of AstraZeneca’s use of Israeli-origin facial recognition, biometric identification, gait analysis, behavioural analytics, predictive policing, social-media monitoring, sentiment analysis or workforce-surveillance products.^{1, 3, 4}

• AstraZeneca Israel’s privacy notice describes market research and segmentation, including AI/ML-enabled metrics based on professional, product-interaction and network-activity information, and says automated tools may generate recommendations, predictions or insights subject to qualified-human final decisions; the notice does not identify an Israeli-origin vendor or biometric, policing or employee-surveillance deployment.⁵

• No public evidence identified that the specified surveillance or biometric technologies reach AstraZeneca through a named managed-security provider or bundled enterprise platform.^{1, 3}

• The reviewed materials describe pharmaceutical research, digital-health collaboration and security-platform relationships, but do not document surveillance, policing or retail-technology applications.^{1, 3, 6}

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

• AstraZeneca is identified as a partner and shareholder in AION Labs, an Israel-based venture studio focused on digital health and computational biology, and AWS is identified as a participant in the initiative.^{7, 8, 9}

• The Israel Innovation Authority lists AION Labs at 4 Oppenheimer Street, Rehovot Science Park, identifies its activity as digital health and computational biology, and does not disclose AstraZeneca’s shareholding percentage, capital commitment or governance rights.⁹

• A June 2026 Innovation Authority report describes eight AION companies formed between November 2023 and February 2025 to develop AI-enabled drug-discovery technologies, but does not disclose AstraZeneca’s stake, data arrangements, Israeli state-security customers or a Project Nimbus relationship.¹⁰

• Public AION material describes a venture-studio model intended to build and validate AI and technology ventures for pharmaceutical research and development, rather than an AstraZeneca general-enterprise cloud deployment.⁸

• AstraZeneca’s Israeli privacy notice identifies AstraZeneca (Israel) Ltd as controller for covered personal data and describes collection and analysis of healthcare-professional and commercial-contact data, including AI/ML-enabled market research and segmentation.⁵

• The notice contemplates sharing data with Group companies, IT providers, healthcare or research partners, and statutory or law-enforcement bodies, as well as cross-jurisdictional transfers; it does not identify a data-centre location, cloud provider, routing, particular retention period, Israeli public-authority access, or whether Wiz or Claroty process this data.⁵

• AstraZeneca’s A.Catalyst material states that BeyondBio currently works with local stakeholders on data collaboration, venture creation and scaling digital-health and AI solutions, without specifying data categories, storage location, processors, cross-border routing, retention, government-access arrangements or security-sector customers.¹¹

• No public evidence identified that AstraZeneca operates or leases Israeli data-centre infrastructure, participates in Project Nimbus, or provides cloud, digital-sovereignty, infrastructure-resilience or data-residency services to Israeli state or military institutions.^{3, 7, 9, 5, 12, 10}

Defence, Intelligence & Security Sector Technology Relationships

• No public evidence identified of AstraZeneca technology contracts, partnerships, services or technology provision to the Israeli Ministry of Defence, IDF, intelligence agencies, police, border authorities or other Israeli security bodies.^{3, 4, 13, 12}

• A 15 September 2025 Israeli Government Procurement Administration notice for “Unique medicines - AstraZeneca” at Sheba Medical Center lists Solomon Levin Elstein Ltd. as supplier; it is a pharmaceutical procurement notice and does not evidence a technology, cloud, AI, data, surveillance or defence contract with AstraZeneca or an AstraZeneca group entity.¹⁴

• No public evidence identified of AstraZeneca commercial technology, including any Wiz or Claroty deployment, being documented for Israeli military, intelligence, law-enforcement, settlement or occupied-territory surveillance use.^{1, 3, 4, 13}

• No public evidence identified of AstraZeneca developing, licensing, selling or maintaining offensive cyber capabilities, exploit tools, digital weapons systems, target-generation systems, fire-control systems, lethality systems or autonomous tracking systems for Israeli state actors.^{3, 4, 13}

AI, Algorithmic & Autonomous Systems

• In December 2020, the Israel Innovation Authority announced the selection of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and AWS to establish an innovation lab for digital health and computational biology.⁷

• AION Labs currently identifies AstraZeneca as a partner in a venture studio supporting AI and technology ventures for pharmaceutical research and development, including engagement with pharmaceutical R&D experts and early-stage companies.⁸

• AstraZeneca states that BeyondBio works with local stakeholders to scale digital-health and AI solutions, but does not identify Israeli state, military, intelligence or law-enforcement customers, or surveillance and targeting applications.¹¹

• The Israel Innovation Authority’s 2026 collaboration call identifies BEAM as an AstraZeneca-led global real-world-evidence research centre established with Tel Aviv University and describes an objective of using decades of Israeli health data to advance patient care in Israel and worldwide.^{12, 15}

• April 2026 BEAM programme guidelines describe prospective pilot areas including clinical-text-mining algorithms for identifying clinical events, diagnoses, medicines and outcomes in free text, and medical-coding automation; these are prospective programme priorities, not evidence of a particular vendor deployment, identified-patient-data transfer, or state-security use.¹⁶

• The guidelines refer to a potential opportunity for participating Israeli companies to develop and validate solutions against AstraZeneca international medical-data environments, but do not identify controllers, datasets, access controls, storage regions, transfers or legal-access arrangements.¹⁶

• Tel Aviv University’s March 2025 launch notice and May 2025 grant call confirm BEAM’s public launch and chronic-disease real-world-data research, with grants of up to NIS 100,000 per project.^{17, 18}

• A January 2026 HealthIL event included BEAM as a case study, with AstraZeneca Israel personnel, the Israeli Ministry of Health’s Head of Policy for Digital Health, health-service representatives and the BEAM research-institute head; the agenda documents event participation, not a Ministry data-sharing agreement, operational control or access to BEAM data.¹⁹

• No public evidence identified of BEAM, AION, BeyondBio or Innovation Authority collaborations providing AI/ML, computer vision or autonomous decision-support systems to Israeli military, intelligence, police or security bodies; using intercepted communications, civilian-surveillance or occupied-territory datasets; or supplying autonomous targeting, fire-control, lethality or autonomous-tracking systems.^{4, 13, 12, 16, 10}

Technology Ecosystem & R&D Footprint

• AstraZeneca PLC is incorporated in England and Wales, and its 2025 Form 20-F defines AstraZeneca or the Group as the company and its consolidated entities.²⁰

• AstraZeneca’s 2025 subsidiary schedule identifies AstraZeneca (Israel) Ltd and Alexion Pharma Israel Ltd as wholly owned Israeli subsidiaries, each with a 100% Group interest.²¹

• The subsidiary schedule gives Kfar Saba addresses for both entities, while AstraZeneca’s privacy-contact page, last updated in August 2026, identifies AstraZeneca (Israel) Ltd at an address in Hod Hasharon; the reviewed sources therefore establish the entity but contain inconsistent current address information.^{21, 22}

• AstraZeneca Israel states that the local operation was established in late 2008, employs more than 100 people in sales, marketing, medical and regulatory affairs, and is expanding clinical-research activity; it does not identify an AstraZeneca-owned Israeli engineering centre or disclose Israeli R&D headcount.³

• AstraZeneca states that it signed a May 2019 memorandum of understanding with the Israeli Innovation Authority to invest in research and digital innovation in Israel, and identifies BeyondBio as the health-innovation hub created in fulfilment of that memorandum.^{3, 11}

• AstraZeneca reports 2019–20 PlayBeyondBio and ARC collaborations involving JVP and Sheba Medical Center, but the reviewed materials do not independently establish their continuing status, contract values, intellectual-property terms, funding recipients or data-access arrangements.³

• A November 2019 JVP announcement described a BeyondBio cooperation agreement with AstraZeneca to identify, develop and invest in Israeli digital-health technologies, and said the programme would support start-ups with access to databases and academic research institutes; the historical announcement does not establish the current programme status or database-access terms.²³

• IATI’s 2025 booklet attributes to AstraZeneca Israel a statement that AZ Global signed a further Israeli Innovation Authority memorandum during 2024 to support Israeli start-ups’ global scaling and that AstraZeneca established BEAM with Tel Aviv University in 2024; the underlying 2024 memorandum and agreement were not located in the reviewed materials.²⁴

• The 2026 AstraZeneca–BEAM pilot call is distinct official evidence of continuing AstraZeneca–Innovation Authority digital-health collaboration after July and November 2024, but does not identify selected participants, signed contracts, completed pilots, data-protection agreements, research protocols or downstream products.^{12, 16}

• No public evidence identified of an AstraZeneca acquisition of an Israeli technology company or a significant disclosed patent licence or co-development arrangement with Technion, Hebrew University or the Weizmann Institute.^{3, 11}

Civil Society Scrutiny & Regulatory History

• AstraZeneca’s current leadership page identifies Michel Demaré as non-executive Chair, Pascal Soriot as Executive Director and CEO, Aradhana Sarin as Executive Director and CFO, and Marcus Wallenberg as a non-executive director; the page also identifies current senior-executive-team members and disclosed outside appointments.⁶

• The disclosed outside appointments include Demaré directorships at Vodafone and Louis Dreyfus International Holding; Soriot directorships at Agilent Technologies and Sustainable Markets Initiative; Sarin’s independent directorship and audit-committee role at Anheuser-Busch InBev; and Wallenberg’s positions at Saab, Wallenberg Investments, FAM, Investor AB and EQT.⁶

• These biographical disclosures do not establish personal or attributable holdings in Israeli cyber, surveillance, AI, SIGINT, military-technology, settlement-linked or Israeli state-security entities.⁶

• At 31 December 2025, AstraZeneca’s disclosed major shareholders were BlackRock, Investor AB, The Capital Group Companies and Wellington Management Group/Company, and AstraZeneca stated that it had not been notified of any other notifiable holding or of direct or indirect control by a corporation or government; no shareholder of 10% or more appears in that disclosure-scoped table.²⁵

• A 19 March 2026 SEC Form 3 identifies Mani Sharma as SVP, Group Controller and Head of Global Finance Services and records direct ordinary-share and employee-plan interests, but does not establish an Israeli technology investment or relevant downstream deployment.²⁶

• No public evidence identified in the bounded review of the Chair, CEO, CFO, directors, senior executives, disclosed shareholders or attributable vehicles of qualifying digital-system provision, investment or deployment for Israeli state, military, intelligence, police, border, settlement or occupation use; this source- and search-scoped conclusion does not rule out non-public, non-notifiable, personal, family-office, trust, foundation or later interests.^{6, 25, 26}

• The supplied document-scoped review found no AstraZeneca mention in UN Special Rapporteur report A/HRC/59/23, the reviewed OHCHR settlement-business database materials and specified NGO reports; this does not establish AstraZeneca’s absence from every edition of every database, campaign, legal record or underlying source.^{13, 27}

• No public evidence identified in the reviewed corporate records, Innovation Authority material, leadership and major-shareholder disclosures, and canonical-report scan of an AstraZeneca or Group-entity facility in the West Bank, East Jerusalem, the Golan Heights or another occupied territory; the reviewed materials do not constitute an audit of all distributors, clinical-trial sites, customers, resellers or data-processing locations.^{3, 21, 22, 27}

• No public evidence identified in the reviewed materials of an organised boycott, divestment or sanctions campaign specifically concerning AstraZeneca technology provision, or of an associated company response.^{3, 11, 13}

• No public evidence identified in the reviewed materials of technology-related regulatory inquiries, export-control cases, sanctions investigations, litigation, court action or parliamentary investigation involving AstraZeneca technology provided to Israeli state or security entities.^{3, 11, 13}